APVO News and Press, Aptevo Therapeutics Inc. From 04/02/19

The following slide deck was published by Aptevo Therapeutics Inc. in conjunction with this Read more ...

APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation from a Competitor Candidate Phase 1/1b Clinical Study of APVO436 Continuing D...

SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates will...

Aptevo Therapeutics (NASDAQ: APVO ) has commenced dosing in a Phase 1 clinical trial of APVO210, a novel bispecific antibody candidate built on ADAPTIR therapeutic protein platform developed to treat autoimmune and inflammatory diseases. More news on: Aptevo Therapeutics Inc., Healthcare...

Unique Mechanism of Action Suppresses Inflammation and Immune Activation  Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 SEATTLE, March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO)...

Aptevo Therapeutics (NASDAQ: APVO ): FY GAAP EPS of -$2.39. More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Achieves Record Annual IXINITY ® Net Revenue of $23.1 Million  Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of  Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence ...

Gainers:  Bio-Path Holdings (NASDAQ: BPTH ) +201% . Seelos Therapeutics (NASDAQ: SEEL ) +79% . ArQule (NASDAQ: ARQL ) +66% . Altimmune (NASDAQ: ALT ) +60% . Rosetta Stone (NYSE: RST ) +31% . Calumet Specialty Products Partners (NASDAQ: CLMT ) +29% . Cleveland BioLabs (NASDAQ: CB...

Aptevo Therapeutics ( APVO -45.1% ) slumps on almost 13x higher volume in response to its public offering of 19.85M shares of common stock and warrants to purchase up to the same number of shares at a price of $1.00 per share and warrant. More news on: Aptevo Therapeutics Inc., Healthc...

Aptevo Therapeutics (NASDAQ: APVO )  -38%  on equity offering . More news on: Aptevo Therapeutics Inc., Resideo Technologies, Inc., Kroger Co., Stocks on the move, Read more ...